Montag A & Associates Inc. Reduces Holdings in Abbott Laboratories $ABT

Montag A & Associates Inc. cut its position in shares of Abbott Laboratories (NYSE:ABT) by 17.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 82,141 shares of the healthcare product maker’s stock after selling 17,167 shares during the period. Montag A & Associates Inc.’s holdings in Abbott Laboratories were worth $7,453,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. Freemont Management S.A. grew its holdings in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories during the 4th quarter valued at about $116,580,000. Thrivent Financial for Lutherans boosted its position in Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after buying an additional 48,286 shares during the period. Aureus Asset Management LLC grew its stake in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after acquiring an additional 66,422 shares in the last quarter. Finally, North Dakota State Investment Board purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $7,439,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first continuous monitor designed to track both glucose and ketone levels. The device could strengthen Abbott’s FreeStyle Libre ecosystem, help identify rising ketones before diabetic ketoacidosis emergencies, and support compatibility with automated insulin-delivery systems. Reuters article
• Positive Sentiment: TD Cowen raised its price target for ABT to $135 from $115 and maintained a “buy” rating. The upgrade signals confidence in Abbott’s growth prospects, particularly in continuous glucose monitoring and medical devices. Benzinga article
• Positive Sentiment: Medtronic’s MiniMed Flex insulin pump has begun shipping with an Abbott-made glucose sensor, expanding the potential distribution and application of Abbott’s sensor technology in automated insulin delivery. MedTech Dive article
• Neutral Sentiment: Recent comparisons portray Abbott as a relatively attractive healthcare and continuous glucose monitoring investment, citing valuation, liquidity and price-target upside. These assessments may support sentiment but do not represent new company operating results. Yahoo Finance article
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formulas contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Insider Monkey article
• Negative Sentiment: Diagnostics growth remains uneven: strong routine testing and 13% cancer-diagnostics growth are being partly offset by weaker respiratory testing demand. This could temper near-term revenue momentum. Yahoo Finance article

Abbott Laboratories Stock Down 0.5%

Shares of NYSE ABT opened at $116.12 on Wednesday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The stock’s fifty day simple moving average is $101.15 and its two-hundred day simple moving average is $100.09. The stock has a market capitalization of $200.94 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the business posted $1.26 EPS. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Robert W. Baird assumed coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. JPMorgan Chase & Co. upped their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.